Quantitative risk analysis for N-methyl pyrrolidone using physiologically based pharmacokinetic and benchmark dose modeling.
暂无分享,去创建一个
Christoph van Thriel | Michael Bader | C. Kirman | M. Gargas | P. Hinderliter | C. van Thriel | Michael L Gargas | T. Poet | Paul M Hinderliter | Torka S Poet | Chris R Kirman | M. Bader
[1] J. Wesche,et al. Doppler Measurements Of Changes In Human Mammary And Uterine Blood Flow During Pregnancy And Lactation , 1988, Acta obstetricia et gynecologica Scandinavica.
[2] Harvey J Clewell,et al. Application of a physiologically based pharmacokinetic model for isopropanol in the derivation of a reference dose and reference concentration. , 2002, Regulatory toxicology and pharmacology : RTP.
[3] P Delorme,et al. Physiologically based pharmacokinetics and the dermal absorption of 2-butoxyethanol vapor by humans. , 1997, Fundamental and applied toxicology : official journal of the Society of Toxicology.
[4] B. Akesson,et al. Experimental exposure of male volunteers to N-methyl-2-pyrrolidone (NMP): acute effects and pharmacokinetics of NMP in plasma and urine. , 1997, Occupational and environmental medicine.
[5] M. Delp,et al. Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.
[6] X. E,et al. A Linear Pharmacokinetic Model Predicts Usefulness of N‐Methyl‐2‐Pyrrolidone (NMP) in Plasma or Urine as a Biomarker for Biological Monitoring for NMP Exposure , 2000 .
[7] Fredrik U. Jönsson,et al. Physiologically based pharmacokinetic modeling of inhalation exposure of humans to dichloromethane during moderate to heavy exercise. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.
[8] W. S. Snyder,et al. Report of the task group on reference man , 1979, Annals of the ICRP.
[9] Helmut Greim,et al. Occupational Toxicants: Critical Data Evaluation for MAK Values and Classification of Carcinogens , 1998 .
[10] C. Bell. Clinical Guide to Laboratory Tests. 3rd edition. Norbert W. Tietz, ed. , 2009 .
[11] Richard A Corley,et al. Evaluation of Physiologically Based Models of Pregnancy and Lactation for Their Application in Children's Health Risk Assessments , 2003, Critical reviews in toxicology.
[12] T. Furukawa. TOXICOKINETICS AND METABOLISM , 2022 .
[13] B. Jönsson,et al. Major metabolic pathway for N-methyl-2-pyrrolidone in humans. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[14] G W Jepson,et al. A partition coefficient determination method for nonvolatile chemicals in biological tissues. , 1994, Fundamental and applied toxicology : official journal of the Society of Toxicology.
[15] S. Baughman,et al. Percutaneous absorption of co-administered N-methyl-2-[14C]pyrrolidinone and 2-[14C]pyrrolidinone in the rat. , 1992, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[16] R. A. Parent,et al. Teratogenicity study of N-methylpyrrolidone after dermal application to Sprague-Dawley rats. , 1982, Fundamental and applied toxicology : official journal of the Society of Toxicology.
[17] B. Jönsson,et al. Biological monitoring of N-methyl-2-pyrrolidone using 5-hydroxy-N-methyl-2-pyrrolidone in plasma and urine as the biomarker. , 2000, Scandinavian journal of work, environment & health.
[18] C. Talsness,et al. Embryotoxic potential of N-methyl-pyrrolidone (NMP) and three of its metabolites using the rat whole embryo culture system. , 2009, Toxicology and applied pharmacology.
[19] D J Paustenbach,et al. Proposed occupational exposure limits for select ethylene glycol ethers using PBPK models and Monte Carlo simulations. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.
[20] K. P. Lee,et al. Toxicity of N-methyl-2-pyrrolidone (NMP): Teratogenic, subchronic, and two-year inhalation studies , 1987 .
[21] A. Saillenfait,et al. Comparative developmental toxicities of the three major metabolites of N‐methyl‐2‐pyrrolidone after oral administration in rats , 2007, Journal of applied toxicology : JAT.
[22] Harvey J Clewell,et al. Evaluation of the potential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactation. , 2003, Regulatory toxicology and pharmacology : RTP.
[23] A. Saillenfait,et al. Developmental toxicity of N-methyl-2-pyrrolidone administered orally to rats. , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[24] M. Blaszkewicz,et al. Human volunteer study on the inhalational and dermal absorption of N-methyl-2-pyrrolidone (NMP) from the vapour phase , 2007, Archives of Toxicology.
[25] A. Saillenfait,et al. Developmental toxicity of N-methyl-2-pyrrolidone in rats following inhalation exposure. , 2003, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[26] N. Tietz. Clinical guide to laboratory tests , 1983 .
[27] F. Gallissot,et al. Developmental toxic effects of N‐ethyl‐2‐pyrrolidone administered orally to rats , 2007, Journal of applied toxicology : JAT.
[28] H J Clewell,et al. Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk. , 1996, Toxicology.
[29] B. Jönsson,et al. Determination of N-methylsuccinimide and 2-hydroxy-N-methylsuccinimide in human urine and plasma. , 1997, Journal of chromatography. B, Biomedical sciences and applications.
[30] E J O'Flaherty,et al. A physiologically based kinetic model of rat and mouse gestation: disposition of a weak acid. , 1992, Toxicology and applied pharmacology.
[31] K. Golka,et al. Chemosensory effects during acute exposure to N-methyl-2-pyrrolidone (NMP). , 2007, Toxicology letters.
[32] B. Jönsson,et al. Determination of 5-hydroxy-N-methylpyrrolidone and 2-hydroxy-N-methylsuccinimide in human urine. , 1997, Journal of chromatography. B, Biomedical sciences and applications.
[33] Toxicokinetics and metabolism of N-[(14)C]N-methyl-2-pyrrolidone in male Sprague-Dawley rats: in vivo and in vitro percutaneous absorption. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[34] B. Jönsson,et al. Evaluation of exposure biomarkers from percutaneous absorption of N-methyl-2-pyrrolidone. , 2004, Scandinavian journal of work, environment & health.
[35] R. E. Staples,et al. 1-Methyl-2-pyrrolidone (NMP): reproductive and developmental toxicity study by inhalation in the rat. , 1995, Drug and chemical toxicology.
[36] R. Wrbitzky,et al. Dermal absorption and urinary elimination of N-methyl-2-pyrrolidone , 2005, International archives of occupational and environmental health.
[37] Harvey J. Clewell,et al. Review and Evaluation of the Potential Impact of Age- and Gender-Specific Pharmacokinetic Differences on Tissue Dosimetry , 2002, Critical reviews in toxicology.
[38] Vera Rogiers,et al. 3.9. Toxicokinetics and Metabolism , 2005, Alternatives to laboratory animals : ATLA.
[39] J. Payan,et al. Toxicokinetics and metabolism of N-[14C]methylpyrrolidone in male Sprague-Dawley rats. A saturable NMP elimination process. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[40] E J O'Flaherty. Physiologically based pharmacokinetic models in developmental toxicology. , 1994, Risk analysis : an official publication of the Society for Risk Analysis.
[41] Horst Braun. Deutsche Forschungsgemeinschaft(DFG) , 1982 .